Core Insights - Healthpeak reported revenue of $694.35 million for the quarter ended June 2025, reflecting a year-over-year decline of 0.2% and a slight miss of 0.03% against the Zacks Consensus Estimate of $694.58 million [1] - The company achieved an EPS of $0.46, which is an increase from $0.21 a year ago, aligning with the consensus EPS estimate [1] - Healthpeak's stock has returned +10.1% over the past month, outperforming the Zacks S&P 500 composite's +5.7% change, but currently holds a Zacks Rank 4 (Sell) indicating potential underperformance in the near term [3] Revenue Breakdown - Interest income and other revenues were reported at $15.81 million, slightly below the three-analyst average estimate of $15.85 million, with a year-over-year increase of +101.8% [4] - Rental and related revenues amounted to $529.69 million, missing the two-analyst average estimate of $538.95 million, showing a year-over-year decline of -3.1% [4] - Resident fees and services generated $148.86 million, also below the two-analyst average estimate of $150.98 million, but reflecting a year-over-year increase of +5.7% [4] - Net Earnings per Share (Diluted) were reported at $0.05, compared to the $0.07 average estimate based on four analysts [4]

Summary of American Healthcare REIT (AHR) 2025 Conference Call Company Overview - **Company Name**: American Healthcare REIT (AHR) - **Market Capitalization**: Approximately $6 billion - **Enterprise Value**: Approximately $7 billion - **Portfolio**: About 300 clinical healthcare real estate properties - **Unique Structure**: 70% of the portfolio is managed under RIDEA (Real Estate Investment and Development in Elderly Affairs) rather than leased, allowing AHR to retain bottom line earnings [9][10][12] Industry Dynamics - **Demographic Trends**: The oldest baby boomers will turn 80 next year, leading to a significant increase in demand for senior housing over the next 15 years [11] - **Supply Constraints**: There has been a significant drop in new construction starts for assisted living since 2018, exacerbated by COVID-19, rising construction costs, and increasing interest rates [12] - **NOI Growth**: AHR has experienced double-digit same-store NOI growth over the past two years, with expectations for continued growth due to favorable supply-demand dynamics in the senior housing sector [12][36] Competitive Advantages - **Managed vs. Leased Exposure**: AHR's higher exposure to managed properties (70%) compared to peers (60% or lower) allows for greater earnings retention and growth potential [13][16] - **Operator Relationships**: AHR's primary operator, Trilogy, manages about 60% of AHR's NOI and has a strong track record in integrated senior health campuses [18][20] - **Regional Focus**: AHR emphasizes building relationships with regional operators to enhance performance and accountability [30][32] Financial Performance and Guidance - **2024 Performance**: Strong performance led to optimistic growth expectations for 2025, with guidance indicating Trilogy same-store NOI growth in the low teens (13-14%) and SHOP same-store NOI growth in the low twenties [36][38] - **Earnings Growth**: Revised guidance for 2025 indicates a midpoint of $1.61 per share, up from $1.41, reflecting significant earnings growth and a reduction in leverage from 9x to 4.5x [42][44] - **Acquisition Pipeline**: AHR has a dynamic acquisition pipeline of over $300 million, focusing on managed segments to improve portfolio quality and returns [45][46][52] Risks and Mitigations - **Medicaid and Medicare Concerns**: AHR acknowledges potential risks from changes in Medicaid but believes that Trilogy's higher quality mix (less than 20% of revenue from Medicaid) mitigates these risks [60][64] - **Rate Growth**: Trilogy's ability to optimize resident mix and focus on value-based care positions it well to continue achieving rate growth despite potential regulatory changes [66][68] Key Takeaways - **Strong Demand**: The aging population and limited new supply create a favorable environment for AHR's growth in senior housing [11][12] - **Operational Excellence**: AHR's focus on managed properties and strong operator relationships are key differentiators in the competitive landscape [10][30] - **Positive Financial Outlook**: Continued double-digit growth in NOI and a robust acquisition strategy support a positive financial outlook for AHR [36][38][45]

Financial Data and Key Metrics Changes - Total revenues for the first quarter were $386.9 million, a 4% increase year over year [7] - Adjusted EBITDAre was $75.1 million, up 17% year over year [7] - Normalized FFO was $14.3 million or $0.06 per share, exceeding analyst consensus estimates [7] - Same property cash basis NOI was $71.5 million, representing a 20.7% increase year over year [16] Business Line Data and Key Metrics Changes - In the SHOP sector, same property NOI was $38.4 million, a 33.6% sequential increase and a 42.1% year over year increase [8] - Average monthly rate in the SHOP segment increased by 4.8% year over year, with occupancy rising by 130 basis points to 80.2% [9] - Medical office and life science portfolio saw same property occupancy at 90.1%, down 10 basis points from the previous quarter [10] Market Data and Key Metrics Changes - The company completed approximately 145,000 square feet of new and renewal leasing activity in the medical office and life science portfolio, with weighted average rents 18.4% higher than prior rents [10] - Known vacates in the medical office building and life science portfolio for 2025 are modest at 115,000 square feet [11] Company Strategy and Development Direction - The company completed $332 million in asset sales to address upcoming debt maturities and deleverage the balance sheet [7] - The active disposition pipeline includes 65 properties, with expected proceeds between $350 million and $400 million [13] - The company aims to enhance portfolio performance by focusing on well-positioned SHOP assets and best-in-class triple net MOB and life science properties [14] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2025 and 2026 debt maturities, with no debt maturities until 2028 thereafter [22] - The company reaffirmed its 2025 SHOP NOI guidance range of $120 million to $135 million, with potential for increase based on trends [23] Other Important Information - The company invested approximately $32 million in capital during the quarter, with $27 million in SHOP communities and $5 million in the medical office and life science portfolio [17] - The company highlighted the publication of the RMR Group's annual sustainability report, showcasing its commitment to sustainability across its portfolio [14] Q&A Session Summary Question: Can you provide some color on the occupancy gains for the first quarter? - Management noted that occupancy improved due to capital investments in communities and operational initiatives [25][26] Question: Is the Aleris Life dividend a one-time payment? - Management indicated that it was more of a one-time dividend, but future dividends could be possible depending on Aleris's performance [27] Question: Why is the SHOP guidance not increased despite strong NOI performance? - Management explained that business interruption proceeds impacted the current quarter's NOI and that they are awaiting clarity on disposition timing [29][31] Question: Any specific reasons for flat operating expenses in SHOP? - Management stated that operating expenses were flat sequentially, with a year-over-year increase of about 3%, and noted savings in insurance premiums [36][37] Question: What are the expectations for pricing on upcoming financings? - Management expects a weighted average interest rate of about 6.5% for upcoming financings, which is favorable compared to existing debt [41]

Core Viewpoint - Healthpeak is expected to report quarterly earnings of $0.46 per share, reflecting a year-over-year increase of 2.2%, with revenues projected at $694.72 million, up 14.5% from the previous year [1]. Group 1: Earnings Estimates - Analysts have maintained the consensus EPS estimate for the upcoming quarter over the last 30 days, indicating stability in their assessments [1]. - The projected 'Revenues- Rental and related revenues' is expected to reach $527.49 million, showing a year-over-year increase of 14.2% [4]. - 'Revenues- Interest income and other' is anticipated to be $16.97 million, representing a significant year-over-year increase of 195.1% [4]. Group 2: Depreciation and Amortization - Analysts estimate 'Depreciation and amortization' to be $274.46 million, compared to $219.22 million reported in the same quarter last year [5]. Group 3: Stock Performance - Over the past month, Healthpeak shares have decreased by 6.4%, while the Zacks S&P 500 composite has declined by 5.6% [5]. - Healthpeak currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5].